Concerns Raised as Too Few U.S. Children Have Received Flu Vaccine
THURSDAY, Dec. 12, 2024 (HealthDay News) — In new data posted this week by the U.S. Centers for Disease Control and Prevention, only 37 percent of children had
Related Articles
Elon Musk asked people to upload their medical data to X so his AI company could learn to interpret MRIs and CT scans
Health care experts are worried about Grok’s potential to breach patient privacy.
Mobile Stroke Treatment Units Provide Faster Treatment for Acute Intracerebral Hemorrhage
A two-center study finds that the enhanced timeliness of care mobile stroke units bring to ischemic stroke applies to intracerebral hemorrhage as well.
How the world came to run on coffee
Coffee was once a little-known delicacy used to aid religious rituals – now we drink more than two billion cups a day.
COVID, H5N1 & more, 12/14/24
Wastewater levels of SARS-CoV-2 are LOW nationally, but are MODERATE in the Midwest as of December 7th according to the CDC.
Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics
In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build a genetic medicine.
Recipe: Easy, Lighter Cornbread
Low in sugar, with lighter oil, this cornbread is a perfect side to any dish — or even on its own!
Health IT agency must survive Trump-era cuts: Micky Tripathi
Micky Tripathi, assistant secretary for technology policy at HHS, offered his predictions for the future of artificial intelligence regulation.
Apple’s foldable iPad could be like ‘two iPad Pros side-by-side’
It may not be an iPad / Mac hybrid, but could be close.
We need to transform women’s healthcare to tackle “medical misogyny”
A new report by the House of Commons Women and Equalities Committee highlights the scandalous “medical misogyny” that has been affecting women in the UK…
Autopsy of a Drug Withdrawal — The Case of Melphalan Flufenamide | NEJM
A December 2022 law introduced a new expedited withdrawal process for accelerated approvals. The first approval withdrawn with this pathway was that of melphalan flufenamide.
